Genmab A/S (GMAB) Expected to Announce Earnings on Wednesday

Genmab A/S (NASDAQ:GMAB) is projected to release its earnings data on Wednesday, February 12th. Analysts expect Genmab A/S to post earnings of $0.28 per share and revenue of $884.02 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $18.69 on Tuesday. The firm has a market capitalization of $12.37 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.54 and a beta of 0.96. The business has a 50 day simple moving average of $20.84 and a 200-day simple moving average of $23.37. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88.

Analyst Ratings Changes

A number of equities analysts recently commented on GMAB shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.